MEI Pharma, Inc.
LITSNASDAQHealthcare·US · USD
$0.91
+0.01 (+1.47%)
Close · 2026-06-29Price
Key statistics
Valuation
Market cap30.55M USD
Enterprise value23.01M USD
Trailing P/E-0.38
Forward P/E0.00
PEG ratio-0.01
Price / sales0.00
Price / book0.56
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-27.69%
Return on equity-159.26%
Income (TTM)
Revenue0.00 USD
Gross profit-1.97M USD
EBITDA-17.13M USD
Net income-60.82M USD
Diluted EPS-$2.08
Rev. growth (YoY)0.00%
Balance sheet
Total cash7.54M USD
Total debt0.00 USD
Debt / equity0.00
Current ratio11.53
Book value / share$1.62
Cash flow (TTM)
Operating cash flow-10.42M USD
Levered free cash flow-13.42M USD
Shares & price
Shares outstanding35.16M
Float26.43M
Held by institutions17.32%
Beta0.04
50-day MA$1.03
200-day MA$1.49
52-week high$9.00
52-week low$0.69
Dividends
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Recent payments
- 2023-11-16$1.75
Earnings (EPS)
DateEst.ActualSurprise2026-05-281.231.28+4.07%2026-04-271.211.28+5.79%2025-10-200.620.65+4.84%2024-09-19-1.40-1.13+19.29%2024-05-09-1.26-1.37−8.73%
About MEI Pharma, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Justin J. File CPA
- Employees
- 4
- Headquarters
- San Diego, CA, United States
- Website
- www.litestrategy.com